Adjuvant platinum-based chemotherapy for early stage cervical cancer

Abstract

Background This is an updated version of the original Cochrane review published in The Cochrane Library 2009, Issue 3. Most women with early cervical cancer (stages I to IIA) are cured with surgery or radiotherapy, or both. We performed this review originally because it was unclear whether cisplatin-based chemotherapy after surgery, radiotherapy or both, in women with early stage disease with risk factors for recurrence, was associated with additional survival benefits or risks. Objectives To evaluate the effectiveness and safety of platinum-based chemotherapy after radical hysterectomy, radiotherapy, or both in the treatment of early stage cervical cancer. Search methods For the original 2009 review, we searched the Cochrane Gynaecological Cancer Group Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2009, Issue 1), MEDLINE, EMBASE, LILACS, BIOLOGICAL ABSTRACTS and CancerLit, the National Research Register and Clinical Trials register, with no language restriction. We handsearched abstracts of scientific meetings and other relevant publications. We extended the database searches to November 2011 for this update. Selection criteria Randomised controlled trials (RCTs) comparing adjuvant cisplatin-based chemotherapy (after radical surgery, radiotherapy or both) with no adjuvant chemotherapy, in women with early stage cervical cancer (stage IA2-IIA) with at least one risk factor for recurrence. Data collection and analysis Two review authors extracted data independently. Meta-analysis was performed using a random-effects model, with death and disease progression as outcomes. Main results For this updated version, we identified three additional ongoing trials but no new studies for inclusion. Three trials including 368 evaluable women with early cervical cancer were included in the meta-analyses. The median follow-up period in these trials ranged from 29 to 42 months. All women had undergone surgery first. Two trials compared chemotherapy combined with radiotherapy to radiotherapy alone; and one trial compared chemotherapy followed by radiotherapy to radiotherapy alone. It was not possible to perform subgroup analyses by stage or tumour size. Compared with adjuvant radiotherapy, chemotherapy combined with radiotherapy significantly reduced the risk of death (two trials, 297 women; hazard ratio (HR) = 0.56, 95% confidence interval (CI): 0.36 to 0.87) and disease progression (two trials, 297 women; HR = 0.47, 95% CI 0.30 to 0.74), with no heterogeneity between trials (I2 = 0% for both meta-analyses). Acute grade 4 toxicity occurred significantly more frequently in the chemotherapy plus radiotherapy group than in the radiotherapy group (risk ratio (RR) 5.66, 95% CI 2.14 to 14.98). We considered this evidence to be of a moderate quality due to small numbers and limited follow-up in the included studies. In addition, it was not possible to separate data for bulky early stage disease. In the one small trial that compared adjuvant chemotherapy followed by radio...

High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer

“…Cervical carcinoma development begins with the infection of the cervical epithelium by high-risk human papillomaviruses (hr-HPVs) [3-5]. Although cervical cancer can be detected in its early stages by HPV testing and Papanicolaou (Pap) smear screening and successfully eradicated through surgery, curative treatments do not yet exist for advanced, recurrent or metastatic disease [6-8]. …”

Comparison of adjuvant therapy for node‐positive clinical stage IB‐IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation

“…Per the National Comprehensive Cancer Network guidelines, use of pelvic irradiation with concurrent administration of weekly chemotherapy (CCRT) is recommended as adjuvant therapy for node‐positive early‐stage cervical cancer . However, a recent meta‐analysis showed that CCRT is associated with increased risk of severe toxicity . Owing to this toxicity profile which is mostly related to radiotherapy, systemic chemotherapy has been considered as an alternative treatment option for adjuvant therapy after primary surgical treatment for this high‐risk group.…”

“…7 However, a recent meta-analysis showed that CCRT is associated with increased risk of severe toxicity. 8 Owing to this toxicity profile which is mostly related to radiotherapy, systemic chemotherapy has been considered as an alternative treatment option for adjuvant therapy after primary surgical treatment for this high-risk group. While some studies suggested a possible utility of systemic chemotherapy, others concluded that systemic chemotherapy does not improve survival outcome.…”

Preoperative Neutrophil-Lymphocyte Ratio Before Platelet-Lymphocyte Ratio Predicts Clinical Outcome in Patients With Cervical Cancer Treated With Initial Radical Surgery

“…2 The prognostic factors affecting the survival of patients with cervical cancer mainly include the International Federation of Obstetricians and Gynecologists (FIGO) tumor staging system, lymph node (LN) status, tumor size, and depth of invasion. 3,4 Except the stage of disease, other variables can only be evaluated after surgery. Therefore, a noninvasive and readily accessible preoperative test to estimate survival probability and prognosis in cervical cancer is necessary.…”